Austria
Sarcura, founded in 2019 and headquartered in Austria, is pioneering a transformative approach in the field of cell therapy manufacturing. Operating at the intersection of Biotechnology, Life Sciences, and Semiconductor industries, Sarcura aims to address the critical challenges of scalability and cost-effectiveness in producing patient-derived cell therapies.
With their slogan, “Powering New Possibles in Cell Therapy Manufacturing,” Sarcura leverages cutting-edge semiconductor technologies, notably silicon photonics, integrated into microfluidic cartridges. Their fully automated manufacturing systems offer real-time process and product control, promising significant improvements in efficiency with a targeted 100x production increase and 10x cost reduction.
Sarcura's last funding round was a €7.05M Seed Round on 17 November 2022, backed by investors including HCVC, Tecnet Equity, Nina Ventures, and others. This infusion of capital underscores investor confidence in their mission to industrialize cell therapy and significantly lower costs, potentially democratizing access to life-saving cancer treatments.
